mRNA Cov Vaccine ja assosiaatio adenopatiaan ja syöpään

e. 2022 Aug;32(8):5752-5758.

doi: 10.1007/s00330-022-08655-0. Epub 2022 Mar 5.

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination

Joao V Horvat  ¹ , Varadan Sevilimedu  ² , Anton S Becker  ³ , Rocio Perez-Johnston  ³ , Randy Yeh  ³ , Kimberly N Feigin  ³

Affiliations

• PMID: 35247087
• PMCID: PMC8897548
• DOI: 10.1007/s00330-022-08655-0

Free PMC article

Abstract

Objectives: To assess the frequency of ipsilateral axillary adenopathy on breast MRI after COVID-19 vaccination. To investigate the duration, outcomes, and associated variables of vaccine-related adenopathy.

Methods: In this retrospective cohort study, our database was queried for patients who underwent breast MRI following COVID-19 vaccination from January 22, 2021, to March 21, 2021. The frequency of ipsilateral axillary adenopathy and possible associated variables were evaluated, including age, personal history of ipsilateral breast cancer, clinical indication for breast MRI, type of vaccine, side of vaccination, number of doses, and number of days between the vaccine and the MRI exam. The outcomes of the adenopathy were investigated, including the duration of adenopathy and biopsy results.

Results: A total of 357 patients were included. The frequency of adenopathy on breast MRI was 29% (104/357 patients). Younger patients and shorter time intervals from the second dose of the vaccine were significantly associated with the development of adenopathy (p = 0.002 for both). Most adenopathy resolved or decreased on follow-up, with 11% of patients presenting persistence of adenopathy up to 64 days after the second dose of the vaccine. Metastatic axillary carcinoma was diagnosed in three patients; all three had a current ipsilateral breast cancer diagnosis.

Conclusions: Vaccine-related adenopathy is a frequent event after COVID-19 vaccination; short-term follow-up is an appropriate clinical approach, except in patients with current ipsilateral breast cancer. Adenopathy may often persist 4-8 weeks after the second dose of the vaccine, thus favoring longer follow-up periods.

Key points: • MRI-detected ipsilateral axillary adenopathy is a frequent benign finding after mRNA COVID-19 vaccination. • Axillary adenopathy following COVID-19 vaccination often persists > 4 weeks after vaccination, favoring longer follow-up periods. • In patients with concurrent ipsilateral breast cancer, axillary adenopathy can represent metastatic carcinoma and follow-up is not appropriate.

Keywords: Breast neoplasms; Lymphadenopathy; Magnetic resonance imaging; Pandemic; Vaccines.

© 2022. The Author(s), under exclusive licence to European Society of Radiology.

PubMed Disclaimer

Seroprevalence of IgM and IgG Against SARS-CoV-2 after Two Doses of Pfizer-BioNTech COVID-19 Vaccine in Women with Breast Cancer.

Almehmadi M, Salih MM, Shafie A, Alsharif A, Alsiwiehr N, El-Askary A, Alzahrani K, Al-Hazmi A, Aljuaid A, Abdulazziz O, Almalki AA, Allahyani M, Eed E, Alharbi AM, Halawi M, Allam HH, Abutawil H, Alosimi E, Gharib AF. Clin Lab. 2022 Nov 1;68(11). doi: 10.7754/Clin.Lab.2022.220316. PMID: 36378000

METHODS: Overall, 103 breast cancer patients were included. Individuals who had had two doses of Pfizer-BioNTech vaccine, patients who were earlier diagnosed with COVID-19 infection, had not finalized immunization plan, or who received the second dose recently were …

5

Lymphadenopathy after the third Covid-19 vaccine.

Özütemiz C, Potter DA, Özütemiz AÖ, Steinberger D. Curr Probl Cancer Case Rep. 2021 Dec;4:100127. doi: 10.1016/j.cpccr.2021.100127. Epub 2021 Oct 30. PMID: 34746900 Free PMC article.

Axillary lymphadenopathy ipsilateral to the vaccination site has been clinically and radiologically reported after administration of COVID-19 vaccines. This can be an important diagnostic dilemma, particularly in cancer patients who are being staged or re-staged, as this benign entity may mimic metastasis, cause unnecessary biopsies and changes in therapy. Here we present a breast cancer patient and a patient with squamous cell carcinoma of the head and neck, who had already received the first two doses of mRNA type COVID-19 vaccines before, now presenting with new hypermetabolic reactive lymphadenopathy on FDG PET/CT after the third booster dose.

Keywords: CDC, The Center for Disease Control; Covid 19; FDA, The United States Food and Drug Administration; RAL, Reactive ipsilateral axillary lymphadenopathy; booster; lymphadenopathy; mRNA; vaccination; vaccine.